Regeneron's Dupixent drives Q2 results amid Eylea weakness
REGN Regeneron Pharmaceuticals Inc
$782.04 -1.10%
View chart & analysis → - 1Regeneron (REGN) Q2 revenue rose 17% year-over-year to $4.3 billion
- 2Dupixent global sales grew 38% to $6 billion, while Sanofi collaboration revenue rose 51% to $2.2 billion
- 3Combined US sales for both Eylea formulations fell 12% to approximately $1 billion, which Dupixent offset
So what's the key point?
Regeneron's Q2 revenue grew 17% because its main drug, Dupixent, sold very well. While sales for the eye disease drug Eylea decreased, Dupixent filled that gap.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.